Jump to content

Muscular dystrophy

From Wikipedia, the free encyclopedia
(Redirected from Adrenomyodystrophy)
Muscular dystrophy
In affected muscle (right), the tissue has become disorganized and the concentration of dystrophin (green) is greatly reduced, compared to normal muscle (left).
SpecialtyNeuromuscular medicine
SymptomsIncreasing weakening, breakdown of skeletal muscles, trouble walking[1][2]
DurationChronic[1]
Types> 30, including Duchenne muscular dystrophy, Becker muscular dystrophy, facioscapulohumeral muscular dystrophy, limb–girdle muscular dystrophy, myotonic dystrophy[1][2]
CausesGenetic (X-linked recessive, autosomal recessive, or autosomal dominant)[2]
Diagnostic methodGenetic testing[2]
TreatmentPharmacotherapy, physical therapy, braces, corrective surgery, assisted ventilation[1][2]
PrognosisDepends on the particular disorder[1]

Muscular dystrophies (MD) are a genetically and clinically heterogeneous group of rare neuromuscular diseases that cause progressive weakness and breakdown of skeletal muscles over time.[1] The disorders differ as to which muscles are primarily affected, the degree of weakness, how fast they worsen, and when symptoms begin.[1] Some types are also associated with problems in other organs.[2]

Over 30 different disorders are classified as muscular dystrophies.[1][2] Of those, Duchenne muscular dystrophy (DMD) accounts for approximately 50% of cases and affects males beginning around the age of four.[1] Other relatively common muscular dystrophies include Becker muscular dystrophy, facioscapulohumeral muscular dystrophy, and myotonic dystrophy,[1] whereas limb–girdle muscular dystrophy and congenital muscular dystrophy are themselves groups of several – usually extremely rare – genetic disorders.

Muscular dystrophies are caused by mutations in genes, usually those involved in making muscle proteins.[2] The muscle protein, dystrophin, is in most muscle cells and works to strengthen the muscle fibers and protect them from injury as muscles contract and relax.[3] It links the muscle membrane to the thin muscular filaments within the cell. Dystrophin is an integral part of the muscular structure. An absence of dystrophin can cause impairments: healthy muscle tissue can be replaced by fibrous tissue and fat, causing an inability to generate force.[4] Respiratory and cardiac complications can occur as well. These mutations are either inherited from parents or may occur spontaneously during early development.[2] Muscular dystrophies may be X-linked recessive, autosomal recessive, or autosomal dominant.[2] Diagnosis often involves blood tests and genetic testing.[2]

There is no cure for any disorder from the muscular dystrophy group.[1] Several drugs designed to address the root cause are currently available including gene therapy (Elevidys), and antisense drugs (Ataluren, Eteplirsen etc.).[2] Other medications used include glucocorticoids (Deflazacort, Vamorolone); calcium channel blockers (Diltiazem); to slow skeletal and cardiac muscle degeneration, anticonvulsants to control seizures and some muscle activity, and Histone deacetylase inhibitors (Givinostat) to delay damage to dying muscle cells.[1] Physical therapy, braces, and corrective surgery may help with some symptoms[1] while assisted ventilation may be required in those with weakness of breathing muscles.[2]

Outcomes depend on the specific type of disorder.[1] Many affected people will eventually become unable to walk[2] and Duchenne muscular dystrophy in particular is associated with shortened life expectancy.

Muscular dystrophy was first described in the 1830s by Charles Bell.[2] The word "dystrophy" comes from the Greek dys, meaning "no, un-" and troph- meaning "nourish".[2]

Signs and symptoms

[edit]
Severe limb deformities and contractures indicative of muscular dystrophy

The signs and symptoms consistent with muscular dystrophy are:[5]

Causes

[edit]

The majority of muscular dystrophies are inherited; the different muscular dystrophies follow various inheritance patterns (X-linked, autosomal recessive or autosomal dominant). In a small percentage of patients, the disorder may have been caused by a de novo (spontaneous) mutation.[9][10]

Diagnosis

[edit]

The diagnosis of muscular dystrophy is based on the results of muscle biopsy, increased creatine phosphokinase (CpK3), electromyography, and genetic testing. A physical examination and the patient's medical history will help the doctor determine the type of muscular dystrophy. Specific muscle groups are affected by different types of muscular dystrophy.[11]

An MRI can be used to assess the white matter of the nervous system and measure the merosin levels in young boys. An absence of merosin in young boys will result with neurological deficits and changes in the white matter.[12]

Classification

[edit]
Disorder name OMIM Gene Inheritance pattern Age of onset Muscles affected Description
Becker muscular dystrophy 300376 DMD XR Childhood Distal limbs progressing to generalised weakness A less severe variant of Duchenne muscular dystrophy,[13] affects predominantly boys.
Congenital muscular dystrophy Multiple Multiple AD, AR At birth Generalised weakness Symptoms include general muscle weakness and possible joint deformities. Disease progresses slowly, and lifespan is shortened.

Congenital muscular dystrophy includes several disorders with a range of symptoms. Muscle degeneration may be mild or severe. Problems may be restricted to skeletal muscle, or muscle degeneration may be paired with effects on the brain and other organ systems.[14]

Several forms of the congenital muscular dystrophies are caused by defects in proteins thought to have some relationship to the dystrophin-glycoprotein complex and to the connections between muscle cells and their surrounding cellular structure. Some forms of congenital muscular dystrophy show severe brain malformations, such as lissencephaly and hydrocephalus.[13]

Duchenne muscular dystrophy 310200 DMD XR Childhood Distal limbs progressing to generalised weakness, involving respiratory muscles The most common childhood form of muscular dystrophy, affects predominantly boys (mild symptoms may occur in female carriers). Characterised by progressive muscle wasting. Clinical symptoms become evident when the child begins walking. By age 10, the child may need braces and by age 12, most patients are unable to walk.[15] Typical lifespans range from 15 to 45.[15] Sporadic mutations in this gene occur frequently.[16]
Distal muscular dystrophy 254130 DYSF AD, AR 20–60 years Distal muscles in hands, forearms and lower legs Progress is slow and not life-threatening.[17]

Miyoshi myopathy, one of the distal muscular dystrophies, causes initial weakness in the calf muscles, and is caused by defects in the same gene responsible for one form of limb–girdle muscular dystrophy.[13]

Emery–Dreifuss muscular dystrophy Multiple Multiple XR, AD, AR Childhood, early teenage years Distal limb muscles, limb-girdle, heart Symptoms include muscle weakness and wasting, starting in the distal limb muscles and progressing to involve the limb–girdle muscles. Most patients also have cardiac conduction defects and arrhythmias.[18][19]
Facioscapulohumeral muscular dystrophy 158900 DUX4 AD Adolescence Face, shoulders, upper arms, progressing to other muscles Causes progressive weakness, initially in the muscles of the face, shoulders, and upper arms. Additional muscles are often affected.[20] Affected individuals can become severely disabled, with 20% requiring a wheelchair by age 50.[21] 30% of cases involve spontaneous mutations.[21] Penetrance and severity seem to be lower in females compared to males.[21][22]
Limb–girdle muscular dystrophy Multiple Multiple AD, AR Any Upper arms and legs The person normally leads a normal life with some assistance. Rare cardiopulmonary complications can be life-threatening.[23]
Myotonic muscular dystrophy 160900
602668 		DMPK
CNBP 		AD Adulthood Skeletal muscles, heart, other muscle groups Presents with myotonia (delayed relaxation of muscles), as well as muscle wasting and weakness.[24] Varies in severity and manifestations and affects many body systems in addition to skeletal muscles, including the heart, endocrine organs, and eyes.[25]
Oculopharyngeal muscular dystrophy 164300 PABPN1 AD, rarely AR 40–50 years Eye muscles, face, throat, pelvis, shoulders

Management

[edit]
Ankle foot orthosis

Currently, there is no cure for muscular dystrophy. In terms of management, physical therapy, occupational therapy, orthotic intervention (e.g., ankle-foot orthosis),[26][27] speech therapy, and respiratory therapy may be helpful.[26] Low intensity corticosteroids such as prednisone, and deflazacort may help to maintain muscle tone.[28] Orthoses (orthopedic appliances used for support) and corrective orthopedic surgery may be needed to improve the quality of life in some cases.[2] The cardiac problems that occur with Emery–Dreifuss muscular dystrophy (EDMD) and myotonic muscular dystrophy may require a pacemaker.[29] The myotonia (delayed relaxation of a muscle after a strong contraction) occurring in myotonic muscular dystrophy may be treated with medications such as quinine.[30]

Low-intensity, assisted exercises, dynamic exercise training, or assisted bicycle training of the arms and legs during a 24-week trial significantly delayed the functional loss of muscular dystrophy. It can be done in a safe and feasible manner, even with boys late in their ambulation stage. However, eccentric exercises, or intense exercises causing soreness should not be used as they can cause further damage.[31]

Occupational therapy assists the individual with MD to engage in activities of daily living (such as self-feeding and self-care activities) and leisure activities at the most independent level possible. This may be achieved with use of adaptive equipment or the use of energy-conservation techniques. Occupational therapy may implement changes to a person's environment, both at home or work, to increase the individual's function and accessibility; furthermore, it addresses psychosocial changes and cognitive decline which may accompany MD, and provides support and education about the disease to the family and individual.[32]

Prognosis

[edit]

Prognosis depends on the individual form of muscular dystrophy. Some dystrophies cause progressive weakness and loss of muscle function, which may result in severe physical disability and a life-threatening deterioration of respiratory muscles or heart. Other dystrophies do not affect life expectancy and only cause relatively mild impairment.[2]

History

[edit]

In the 1860s, descriptions of boys who grew progressively weaker, lost the ability to walk, and died at an early age became more prominent in medical journals. In the following decade,[33] French neurologist Guillaume Duchenne gave a comprehensive account of the most common and severe form of the disease, which now carries his name – Duchenne MD.[34]

Society and culture

[edit]

In 1966 in the US and Canada, Jerry Lewis and the Muscular Dystrophy Association (MDA) began the annual Labor Day telecast The Jerry Lewis Telethon, significant in raising awareness of muscular dystrophy in North America. Disability rights advocates, however, have criticized the telethon for portraying those living with the disease as deserving pity rather than respect.[35]

On December 18, 2001, the MD CARE Act was signed into law in the US; it amends the Public Health Service Act to provide research for the various muscular dystrophies. This law also established the Muscular Dystrophy Coordinating Committee to help focus research efforts through a coherent research strategy.[36][37]

Research and Advocacy

[edit]

The [Muscular Dystrophy Association](https://en.wikipedia.org/wiki/Muscular_Dystrophy_Association) (MDA) is involved in research, advocacy, and services for individuals affected by muscular dystrophy. The organization provides resources that contribute to understanding and addressing this condition.

See also

[edit]

References

[edit]
  1. ^ a b c d e f g h i j k l m n "NINDS Muscular Dystrophy Information Page". NINDS. March 4, 2016. Archived from the original on 30 July 2016. Retrieved 12 September 2016.
  2. ^ a b c d e f g h i j k l m n o p q r "Muscular Dystrophy: Hope Through Research". NINDS. March 4, 2016. Archived from the original on 30 September 2016. Retrieved 12 September 2016.
  3. ^ Gao, Q. Q.; McNally, E. M. (2011-01-17). Terjung, Ronald (ed.). Comprehensive Physiology. Vol. 5 (1 ed.). Wiley. pp. 1223–1239. doi:10.1002/cphy.c140048. ISBN 978-0-470-65071-4. PMC 4767260. PMID 26140716.
  4. ^ Gao, Quan Q.; McNally, Elizabeth M. (2015-06-24). "The Dystrophin Complex: Structure, Function, and Implications for Therapy". Comprehensive Physiology. 5 (3): 1223–1239. doi:10.1002/cphy.c140048. ISBN 9780470650714. PMC 4767260. PMID 26140716.
  5. ^ Muscular Dystrophy Clinical Presentation at eMedicine
  6. ^ a b El-Sobky, Tamer A.; Abdulhady, Hala; Mahmoud, Shady; Amen, John (31 January 2024). "Orthopedic manifestations of congenital muscular dystrophy subtypes in children: Emerging signatures need consolidation: a scoping review". Journal of Musculoskeletal Surgery and Research. 8: 11–23. doi:10.25259/JMSR_229_2023.
  7. ^ Birnkrant, DJ; Bushby, K; Bann, CM; Alman, BA; Apkon, SD; Blackwell, A; Case, LE; Cripe, L; Hadjiyannakis, S; Olson, AK; Sheehan, DW; Bolen, J; Weber, DR; Ward, LM (April 2018). "Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management". The Lancet. Neurology. 17 (4): 347–361. doi:10.1016/S1474-4422(18)30025-5. PMC 5889091. PMID 29395990.
  8. ^ Bădilă, E; Lungu, II; Grumezescu, AM; Scafa Udriște, A; Rosenthal, David; Duboc, Denis; Melacini, Paola (12 May 2021). "Diagnosis of Cardiac Abnormalities in Muscular Dystrophies". Medicina (Kaunas, Lithuania). 57 (5): 488. doi:10.3390/medicina57050488. PMC 8151418. PMID 34066119.
  9. ^ Choices, NHS. "Muscular dystrophy - Causes - NHS Choices". www.nhs.uk. Archived from the original on 2016-04-02. Retrieved 2016-04-10.
  10. ^ Griffiths, Anthony JF; Miller, Jeffrey H.; Suzuki, David T.; Lewontin, Richard C.; Gelbart, William M. (2000). Spontaneous mutations.[page needed]
  11. ^ "NIH /How is muscular dystrophy diagnosed?". NIH.gov. NIH. 2015. Archived from the original on 7 April 2016. Retrieved 10 April 2016.
  12. ^ Emery, Alan EH (2002-02-23). "The muscular dystrophies". The Lancet. 359 (9307): 687–695. doi:10.1016/S0140-6736(02)07815-7. ISSN 0140-6736. PMID 11879882. S2CID 31578361.
  13. ^ a b c May 2006 report to Congress Archived 2014-04-05 at the Wayback Machine on Implementation of the MD CARE Act, as submitted by Department of Health and Human Service's National Institutes of Health
  14. ^ Congenital Muscular Dystrophy~clinical at eMedicine
  15. ^ a b "Duchenne muscular dystrophy: MedlinePlus Medical Encyclopedia". medlineplus.gov. Archived from the original on 2017-04-05. Retrieved 2017-03-14.
  16. ^ "Duchenne Muscular Dystrophy. What is muscular dystrophy? | Patient". Patient.info. 2016-04-15. Archived from the original on 2016-12-02. Retrieved 2017-03-14.
  17. ^ Udd, Bjarne (2011). "Distal muscular dystrophies". Handbook of Clinical Neurology. Vol. 101. pp. 239–62. doi:10.1016/B978-0-08-045031-5.00016-5. ISBN 978-0-08-045031-5. PMID 21496636.
  18. ^ "OMIM Entry - # 310300 - EMERY-DREIFUSS MUSCULAR DYSTROPHY 1, X-LINKED; EDMD1". Omim.org. Archived from the original on 2017-03-10. Retrieved 2017-03-14.
  19. ^ "Emery-Dreifuss muscular dystrophy - Genetics Home Reference". Ghr.nlm.nih.gov. 2017-03-07. Archived from the original on 2017-03-12. Retrieved 2017-03-14.
  20. ^ "facioscapulohumeral muscular dystrophy - Genetics Home Reference". Ghr.nlm.nih.gov. Archived from the original on 2017-03-24. Retrieved 2017-03-14.
  21. ^ a b c Statland, JM; Tawil, R (December 2016). "Facioscapulohumeral Muscular Dystrophy". Continuum (Minneapolis, Minn.). 22 (6, Muscle and Neuromuscular Junction Disorders): 1916–1931. doi:10.1212/CON.0000000000000399. PMC 5898965. PMID 27922500.
  22. ^ "Facioscapulohumeral muscular dystrophy: MedlinePlus Medical Encyclopedia". Nlm.nih.gov. 2017-03-09. Archived from the original on 2016-07-04. Retrieved 2017-03-14.
  23. ^ Jenkins, Simon P.R. (2005). Sports Science Handbook:I - Z. Brentwood, Essex: Multi-Science Publ. Co. p. 121. ISBN 978-0906522-37-0.
  24. ^ Turner, C.; Hilton-Jones, D. (2010). "The myotonic dystrophies: diagnosis and management" (PDF). Journal of Neurology, Neurosurgery & Psychiatry. 81 (4): 358–67. doi:10.1136/jnnp.2008.158261. PMID 20176601. S2CID 2453622.
  25. ^ Bird, T. D.; Adam, M. P.; Everman, D. B.; Mirzaa, G. M.; Pagon, R. A.; Wallace, S. E.; Bean LJH; Gripp, K. W.; Amemiya, A. (1993). "Myotonic Dystrophy Type 1". Myotonic Dystrophy Type 1 - GeneReviews® - NCBI Bookshelf. University of Washington, Seattle. PMID 20301344. Archived from the original on 2017-01-18. Retrieved 2017-03-14. {{cite book}}: |website= ignored (help)
  26. ^ a b "What are the treatments for muscular dystrophy?". NIH.gov. NIH. 2015. Archived from the original on 7 April 2016. Retrieved 10 April 2016.
  27. ^ "Muscular Dystrophy-OrthoInfo - AAOS". orthoinfo.aaos.org. Archived from the original on 2016-04-12. Retrieved 2016-04-10.
  28. ^ McAdam, Laura C.; Mayo, Amanda L.; Alman, Benjamin A.; Biggar, W. Douglas (2012). "The Canadian experience with long term deflazacort treatment in Duchenne muscular dystrophy". Acta Myologica. 31 (1): 16–20. PMC 3440807. PMID 22655512.
  29. ^ Verhaert, David; Richards, Kathryn; Rafael-Fortney, Jill A.; Raman, Subha V. (January 2011). "Cardiac Involvement in Patients With Muscular Dystrophies". Circulation: Cardiovascular Imaging. 4 (1): 67–76. doi:10.1161/CIRCIMAGING.110.960740. PMC 3057042. PMID 21245364.
  30. ^ Eddy, Linda L. (2013). Caring for Children with Special Healthcare Needs and Their Families: A Handbook for Healthcare Professionals. John Wiley & Sons. ISBN 978-1-118-51797-0.[page needed]
  31. ^ Jansen, Merel; Van Alfen, Nens; Geurts, Alexander C. H.; De Groot, Imelda J. M. (2013). "Assisted Bicycle Training Delays Functional Deterioration in Boys with Duchenne Muscular Dystrophy". Neurorehabilitation and Neural Repair. 27 (9): 816–827. doi:10.1177/1545968313496326. PMID 23884013. S2CID 9990910.
  32. ^ Lehman, R. M.; McCormack, G. L. (2001). "Neurogenic and Myopathic Dysfunction". In Pedretti, Lorraine Williams; Early, Mary Beth (eds.). Occupational Therapy: Practice Skills for Physical Dysfunction (5th ed.). Mosby. pp. 802–3. ISBN 978-0-323-00765-8.
  33. ^ Laing, Nigel G; Davis, Mark R; Bayley, Klair; Fletcher, Sue; Wilton, Steve D (2011). "Molecular Diagnosis of Duchenne Muscular Dystrophy: Past, Present and Future in Relation to Implementing Therapies". The Clinical Biochemist Reviews. 32 (3): 129–134. PMC 3157948. PMID 21912442.
  34. ^ "Muscular Dystrophy: Hope Through Research". National Institute of Neurological Disorders and Stroke. 23 March 2020. Retrieved 7 April 2020.
  35. ^ Berman, Ari (2011-09-02). "The End of the Jerry Lewis Telethon—It's About Time". The Nation. Retrieved 2017-03-14.
  36. ^ H.R. 717--107th Congress (2001) Archived 2012-02-19 at the Wayback Machine: MD-CARE Act, GovTrack.us (database of federal legislation), (accessed Jul 29, 2007)
  37. ^ Public Law 107-84 Archived 2012-11-07 at the Wayback Machine, PDF as retrieved from NIH website

Further reading

[edit]
[edit]
Scholia has a topic profile for Muscular dystrophy.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Muscular_dystrophy&oldid=1256087435"